Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 11 Results

Title
Intervention Indication Therapeutic Area Year Actions
Epcoritamab for treating relapsed or refractory follicular lymphoma Epcoritamab (GEN-3013) Follicular lymphoma Haematological Cancer and Lymphomas 2023 View  |  Download
Ibrutinib for the treatment of relapsed or refractory follicular lymphoma Ibrutinib (Imbruvica) Follicular lymphoma Haematological Cancer and Lymphomas 2017 View  |  Download
Lenalidomide (Revlimid) + rituximab for relapsed/refractory follicular lymphoma and marginal zone lymphoma Lenalidomide (Revlimid) , Rituximab (MabThera; Rituxan; RG 105) Follicular lymphoma , Marginal zone lymphoma (MZL) Haematological Cancer and Lymphomas 2017 View  |  Download
Lenalidomide (Revlimid) in combination with rituximab for untreated follicular lymphoma Lenalidomide (Revlimid) , Rituximab (MabThera; Rituxan; RG 105) Follicular lymphoma Haematological Cancer and Lymphomas 2017 View  |  Download
Lisocabtagene maraleucel for transplant-eligible and ineligible, relapsed or refractory, aggressive B-cell non-Hodgkin lymphoma - second-line Lisocabtagene maraleucel (Liso-cel; JCAR017) Diffuse large B-cell lymphoma (DLBCL) , Follicular lymphoma , Non-Hodgkin lymphoma (NHL) , Primary mediastinal large B-cell lymphoma (PMBCL) Haematological Cancer and Lymphomas 2020 View  |  Download
Mosunetuzumab (subcutaneous injection) for treating relapsed or refractory follicular lymphoma Mosunetuzumab (BTCT4465A) Follicular lymphoma Haematological Cancer and Lymphomas 2024 View  |  Download
Mosunetuzumab for relapsed or refractory B-cell follicular lymphoma – third-line and greater Mosunetuzumab (BTCT4465A) Follicular lymphoma Haematological Cancer and Lymphomas 2021 View  |  Download
Tafasitamab with lenalidomide as add-on therapy for previously treated follicular lymphoma or marginal zone lymphoma Lenalidomide (Revlimid) , Tafasitamab (MOR208; Monjuvi) Follicular lymphoma , Marginal zone lymphoma (MZL) Haematological Cancer and Lymphomas 2023 View  |  Download
Tazemetostat for treating relapsed or refractory
follicular lymphoma after two therapies
Tazemetostat (E7438;EPZ-6438;Tazverik) Follicular lymphoma Haematological Cancer and Lymphomas 2023 View  |  Download
Tisagenlecleucel for relapsed or refractory follicular lymphoma Tisagenlecleucel-T (Kymriah; CTL019) Follicular lymphoma Haematological Cancer and Lymphomas 2021 View  |  Download
1 2
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications